The new Lipitor (atorvastatin) management strategy refers to the methods and guidelines set in place for the use and prescription of this cholesterol-lowering drug. However, the specifics of this new strategy are not provided in the question. Nonetheless, Lipitor's general effectiveness as a medication is well-documented and recognized.
Lipitor is a statin, a class of drugs that works by blocking a substance your body needs to make cholesterol. It has been extensively studied and is known to effectively lower LDL (bad) cholesterol and triglycerides, while increasing HDL (good) cholesterol [1]. According to DrugPatentWatch.com, Lipitor has been prescribed to over 29 million patients worldwide, demonstrating its widespread use and acceptance in the medical community [2].
The new management strategy could refer to various aspects such as dosage, combination with other drugs, patient selection, or monitoring parameters. For instance, a study published in the American Journal of Cardiology found that high-intensity statin therapy, such as Lipitor, is safe and effective in reducing cardiovascular events in patients with acute coronary syndrome [3].
In conclusion, while the specifics of the new Lipitor management strategy are not provided, the drug itself has been proven to be effective in managing cholesterol levels and reducing the risk of cardiovascular events. Any new strategy would likely aim to enhance these benefits and improve patient outcomes.
Sources:
[1] Mayo Clinic. (2021). Atorvastatin (Oral Route). Retrieved from https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/description/drg-20062854
[2] DrugPatentWatch.com. (2021). Lipitor (Atorvastatin) Drug Patent Expiration & Generic Launch Dates. Retrieved from https://www.drugpatentwatch.com/drugs/lipitor
[3] Cannon, C. P., Braunwald, E., McCabe, C. H., D'Agostino, R. B., White, J. A., Theroux, P., ... & Montalescot, G. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15), 1495-1504.